• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗心律失常药物的分类。

Classification of antiarrhythmic drugs.

作者信息

Frumin H, Kerin N Z, Rubenfire M

机构信息

Department of Medicine, Sinai Hospital of Detroit, Michigan 48235-2099.

出版信息

J Clin Pharmacol. 1989 May;29(5):387-94. doi: 10.1002/j.1552-4604.1989.tb03350.x.

DOI:10.1002/j.1552-4604.1989.tb03350.x
PMID:2661597
Abstract

Although many classification schemes for antiarrhythmic drugs have been proposed, the system introduced by Vaughan Williams and later modified by Harrison has been widely accepted. This classification system is comprised of four categories. Class I agents block sodium channels. Class II agents are Beta blockers. Class III agents prolong the cardiac action potential. Class IV agents are calcium channel blockers. This classification scheme, based largely on clinical observation continues to be useful almost two decades after its introduction. The electrophysiologic bases, strengths and weaknesses of this system are discussed.

摘要

虽然已经提出了许多抗心律失常药物的分类方案,但由沃恩·威廉姆斯提出并随后由哈里森修改的系统已被广泛接受。该分类系统由四类组成。I类药物阻断钠通道。II类药物是β受体阻滞剂。III类药物延长心脏动作电位。IV类药物是钙通道阻滞剂。这个主要基于临床观察的分类方案在引入近二十年后仍然有用。本文讨论了该系统的电生理基础、优点和缺点。

相似文献

1
Classification of antiarrhythmic drugs.抗心律失常药物的分类。
J Clin Pharmacol. 1989 May;29(5):387-94. doi: 10.1002/j.1552-4604.1989.tb03350.x.
2
Antiarrhythmic agents and proarrhythmia.抗心律失常药物与致心律失常作用
Crit Care Med. 2000 Oct;28(10 Suppl):N158-64. doi: 10.1097/00003246-200010001-00008.
3
Classification and mechanism of action of antiarrhythmic drugs.
Fundam Clin Pharmacol. 1994;8(5):385-90. doi: 10.1111/j.1472-8206.1994.tb00817.x.
4
Therapeutic drug monitoring: antiarrhythmic drugs.治疗药物监测:抗心律失常药物
Br J Clin Pharmacol. 1998 Oct;46(4):307-19. doi: 10.1046/j.1365-2125.1998.t01-1-00768.x.
5
Therapeutic drug monitoring: antiarrhythmic drugs.治疗药物监测:抗心律失常药物
Br J Clin Pharmacol. 2001;52 Suppl 1(Suppl 1):21S-34S. doi: 10.1046/j.1365-2125.2001.0520s1021.x.
6
Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions.抗心律失常药物的进化、作用机制及分类:聚焦III类作用
Am J Cardiol. 1999 Nov 4;84(9A):11R-19R. doi: 10.1016/s0002-9149(99)00697-9.
7
Modernized Classification of Cardiac Antiarrhythmic Drugs.心脏抗心律失常药物的现代化分类。
Circulation. 2018 Oct 23;138(17):1879-1896. doi: 10.1161/CIRCULATIONAHA.118.035455.
8
[Antiarrhythmic agents. Receptor hypothesis explains mechanisms of action].
Tidsskr Nor Laegeforen. 1991 Oct 30;111(26):3187-9.
9
[Vaughan Williams class IV antiarrhythmic drugs].[ Vaughan Williams Ⅳ类抗心律失常药物]
Nihon Rinsho. 1996 Aug;54(8):2132-7.
10
[Current classification of anti-arrhythmia agents].[抗心律失常药物的当前分类]
Z Kardiol. 2000;89 Suppl 3:62-7.

引用本文的文献

1
Nicorandil as a promising therapeutic option for ventricular arrhythmia: A case report and review of literature.尼可地尔作为室性心律失常的一种有前景的治疗选择:一例病例报告及文献综述。
World J Cardiol. 2024 Dec 26;16(12):768-775. doi: 10.4330/wjc.v16.i12.768.
2
Lidocaine as an anti-arrhythmic drug: Are there any indications left?利多卡因作为抗心律失常药物:还有适应证吗?
Clin Transl Sci. 2023 Dec;16(12):2429-2437. doi: 10.1111/cts.13650. Epub 2023 Oct 2.
3
Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease.
治疗 COVID-19 合并心血管疾病患者的药物治疗。
Expert Opin Pharmacother. 2021 Dec;22(18):2455-2474. doi: 10.1080/14656566.2021.1960311. Epub 2021 Aug 31.
4
Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.抗心律失常药物分类。对其历史、现状及临床相关性的批判性评价。
Drugs. 1991 May;41(5):672-701. doi: 10.2165/00003495-199141050-00002.
5
Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.胺碘酮。其药理特性概述及其在心律失常治疗中的应用综述。
Drugs. 1992 Jan;43(1):69-110. doi: 10.2165/00003495-199243010-00007.